The prognostic significance of ALDH1A1 expression in early invasive breast cancer by Althobiti, Maryam et al.
The prognostic significance of ALDH1A1 expression in early
invasive breast cancer
Maryam Althobiti,1,2,3 Rokaya El Ansari,1,2 Mohammed Aleskandarany,1,2
Chitra Joseph,1,2 Michael S Toss,1,2 Andrew R Green1,2 & Emad A Rakha1,2
1Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of
Nottingham Biodiscovery Institute, Nottingham, UK, 2The University of Nottingham and Nottingham University
Hospitals NHS Trust, Nottingham City Hospital, Nottingham, UK, and 3Department of Clinical Laboratory Science,
College of Applied Medical Science, Shaqra, Saudi Arabia
Date of submission 24 January 2020
Accepted for publication 28 April 2020
Published online Article Accepted 5 May 2020
Althobiti M, El Ansari R, Aleskandarany M, Joseph C, Toss M S, Green A R & Rakha E A
(2020) Histopathology 77, 437–447. https://doi.org/10.1111/his.14129
The prognostic significance of ALDH1A1 expression in early invasive breast cancer
Aims: Aldehyde dehydrogenase family 1 member A1
(ALDH1A1) is reportedly a key ALDH isozyme linked
to the cancer stem cells (CSC) of many solid tumours,
where it is involved in self-renewal, differentiation
and self-protection. In this study, the prognostic sig-
nificance of ALDH1A1 expression in early invasive
breast cancer (BC) and its role as a BC stem cell
(BCSC) were evaluated.
Methods and results: ALDH1A1 expression was
assessed, using immunohistochemistry and tissue
microarrays, in a large well-characterised BC cohort.
ALDH1A1 mRNA expression was also assessed at
transcriptomic levels, utilising data from the Molecu-
lar Taxonomy of Breast Cancer International Consor-
tium. The associations of ALDH1A1 with
clinicopathological parameters, other stem cell mark-
ers and patient outcomes were determined. ALDH1A1
was expressed in 71% of BC cases at both the protein
and mRNA levels. High ALDH1A1 expression was
associated with poor prognostic features, including
high grade, poor Nottingham Prognostic Index (NPI),
lymph node metastasis and highly proliferative ER+
(luminal B) and triple-negative (TNBC) subtypes.
ALDH1A1 expression was positively correlated with
the expression of CD44, CD24, TWIST, SOX9, EPCAM
and CD133. The high immunoexpression of
ALDH1A1 was significantly associated with poor BC-
specific survival (P < 0.001), and specifically in the
luminal B and TNBC subtypes (P = 0.042 and
P = 0.003, respectively). The immunoexpression of
ALDH1A1 was an independent predictor of poor
prognosis (P = 0.015).
Conclusions: ALDH1A1, as assessed using immuno-
histochemistry, seems to act as a BCSC marker asso-
ciated not only with other BCSC markers but also
with poor prognostic characteristics and poor out-
comes, particularly in the luminal B and TNBC sub-
types.
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Introduction
Breast cancer (BC) remains a life-threatening disease
despite the advanced achievements in BC therapy.1
Worldwide, it is the second most common cause of
cancer-related mortality among women.2 Cancer
stem cells (CSC) are a subpopulation of cells within
the primary tumour mass, which possess self-renewal,
differentiation and potential tumorigenic properties.3
The identification of CSC-specific biomarkers has been
validated in BC models and has been shown to play a
key role in drug resistance and poor BC outcomes.4,5
Some molecular biomarkers have been studied
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previously in cancer and identified as BCSCs, includ-
ing aldehyde dehydrogenase family 1 member A1
(ALDH1A1), CD44, CD24 and CD133.6,7 ALDH1 is
the most common BCSC marker, and has been stud-
ied in both in-vitro and in-vivo BC models.8 ALDH1 is
an enzyme that catalyses aldehydes to carboxylic
acids and is also involved in the metabolism of sev-
eral aliphatic and aromatic aldehydes.9 ALDH1A1
isozyme oxidises retinaldehyde to retinoic acid, which
regulates the expression of the genes involved in
tumour-initiating stem-like cells, thereby initiating
tumour growth and resistance to drugs.10,11 Much
emphasis has been placed on ALDH1A1 as a CSC
marker. High expression of ALDH1A1 has been
reported as a poor prognostic marker in several
tumour types and is associated with poor patient out-
comes.12,13 However, the clinical significance of
ALDH1A1 expression in human BC using immuno-
histochemistry (IHC) needs to be defined. This study,
therefore, assessed the mRNA and protein expression
of ALDH1A1 in BC with an emphasis on their corre-
lation with other BCSCs markers, as well as with clin-
icopathological features and patient outcomes.
Materials and methods
T U M O U R C H A R A C T E R I S T I C S O F T H E S T U D Y
C O H O R T ( I H C )
The study cohort for the evaluation of ALDH1A1 pro-
tein expression comprised 930 early-stage (I–III) inva-
sive BCs without distant metastases at the time of
diagnosis (M0) derived from a retrospective series of
primary breast carcinoma patients presenting at Not-
tingham City Hospital between 1988 and 1998.14
The patients’ clinical and pathological data included
age at diagnosis, histological tumour type, tumour
size, nodal stage (based on the Nottingham system for
nodal stage: stage 1 for node-negative, stage 2 for
one to three positive nodes and stage 3 for four or
more positive nodes), Nottingham Prognostic Index
(NPI) and lymphovascular invasion (LVI) status. Sur-
vival data were available and prospectively main-
tained, including (i) BC-specific survival (BCSS),
defined as the duration (in months) from the date of
the primary surgical treatment to the time of death
from BC, and (ii) distant metastasis-free survival
(DMFS), defined as the duration (in months) from
surgery to the first event of distant metastasis.15,16
The mean follow-up period of the study cohort was
130 months, median was 120 months and the range
was 239 months. Patients were uniformly treated
based on tumour features, NPI and hormone receptor
status. Endocrine therapy was given to patients who
had ER+ tumours with high NPI scores (>3.4),
whereas no adjuvant therapy was given to patients
with excellent NPI scores (≤3.4). Premenopausal
patients with moderate and poor NPI scores were
candidates for chemotherapy, while postmenopausal
patients with moderate or poor NPI scores were given
hormonal therapy only. None of the patients in the
current study cohort received neoadjuvant therapy.
Data for the expression of oestrogen receptor (ER),
progesterone receptor (PgR) and human epidermal
growth factor receptor 2 (HER2), as well as Ki67,
were also available.17,18 Hormone receptor and HER2
status were assessed according to the recent ASCO
guidelines. ER and PgR positivity were defined as
≥1%. HER2 positivity was defined as ≥10% of tumour
cells showing strong membranous staining as score
+3, where chromogenic in-situ hybridisation tech-
nique (CISH) was used to assess the gene amplifica-
tion status in borderline cases (+2). Ki67 was
considered positive/high if ≥10% of invasive BC cells
showed nuclear positivity. BC molecular subtypes
including luminal A (ER+/HER2; Ki67 < 10%),
luminal B (ER+/HER2; Ki67 ≥ 10%), HER2-positive
class (HER2+ regardless of ER status) and TN (ER,
PgR and HER2) were defined based on IHC pro-
file.19,20
Immunohistochemical expression of BC stem cell-
like markers, including CD133, CD24, CD44, TWIST
(unpublished data), EPCAM and SOX9 (unpublished
data), was previously performed and scored.21–23 The
number of informative cases scored per each marker
was variable based on the available tissue microarray
(TMA) cores.
The clinicopathological parameters for this study
cohort are summarised in Table 1.
A L D H 1 A 1 A N T I B O D Y V A L I D A T I O N
The specificity of the anti-ALDH1A1 antibody (rabbit
monoclonal, HPA002123; Sigma-Aldrich, Poole, UK)
was validated using Western blotting in MCF7 and
HeLa human cell-line lysates, obtained from the
American Type Culture Collection (Rockville, MD,
USA). The ALDH1A1 primary antibody dilution used
was 1:250, and the mouse monoclonal primary anti-
body beta-actin (diluted to 1:5000; Sigma-Aldrich)
was used as a loading control. IRDye 800CW donkey
antirabbit fluorescent secondary antibody and IRDye
800CW donkey antimouse fluorescent secondary
antibody (LI-COR Biosciences, Lincoln, NE, USA) were
used at a dilution of 1:15000. Odyssey Fc with Image
Studio version 4.0 was used to visualise the protein
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 77, 437–447.
438 M Althobiti et al.
bands (LI-COR Biosciences). A single band for
ALDH1A1 was observed at 56 kDa (the predicted
size), which confirmed the specificity of the antibody
(Figure S1A).
T I S S U E M I C R O A R R A Y A N D I H C
Formalin-fixed paraffin-embedded (FFPE) BC tissue
samples were arrayed as described previously,24 and
constructed using a GrandMaster TMA arrayer
Machine (3DHISTECH, Budapest, Hungary), where a
0.6-mm core was removed from the donor blocks to
the recipient blocks. Each case was represented by a
single core taken from the invasive edge of the
tumour.
IHC staining was performed on 4-lm TMA sections
using a Novolink polymer detection system (Leica,
Newcastle, UK). In brief, the slides with the TMA sec-
tions were dewaxed and rehydrated. Antigen retrieval
was performed in a citrate buffer (pH 6.0) in a
Table 1. The association of ALDH1A1 expression and clini-
copathological parameters in invasive breast cancer Not-
tingham cohort for IHC protein expression
Parameters
ALDH1A1 expression (IHC)
N (%)
Low,
N (%)
High,
N (%)
v2
P-
value
Patient age (years)
<50 594 (64) 178 (30) 416 (70) 1.99
≥50 332 (36) 85 (26) 247 (74) 0.158
Tumour size (cm)
≤2 467 57) 126 (27) 341 (73) 0.730
>2 355 (43) 134 (30) 320 (70) 0.90
Tumour grade
Grade 1 148 (19) 50 (38) 82 (62) 9.91
Grade 2 263 (34) 87 (30) 202 (70) 0.007
Grade 3 373 (47) 123 (25) 378 (75)
Tubule formation
1 34 (4) 12 (35) 22 (65) 1.14
2 301 (34) 83 (27) 228 (73) 0.564
3 553 (62) 151 (27) 402 (73)
Mitotic count scores
1 264 (29) 91 (35) 173 (65) 11.29
2 188 (21) 53 (28) 135 (72) 0.004
3 446 (50) 102 (23) 344 (77)
Nuclear pleomorphism
1 18 (2) 9 (50) 9 (50) 13.76
2 311 (35) 103 (33) 208 (67) 0.001
3 567 (63) 134 (24) 433 (76)
Axillary nodal stage*
Stage 1 527 (65) 173 (30) 399 (70) 12.81
Stage 2 213 (27) 57 (21) 216 (79) 0.002
Stage 3 66 (8) 30 (39) 47 (61)
Nottingham Prognostic Index
Good prognostic
group
206 (26) 90 (36) 116 (64) 9.58
Moderate
prognostic group
408 (50) 26 (26) 382 (74) 0.008
Table 1. (Continued)
Parameters
ALDH1A1 expression (IHC)
N (%)
Low,
N (%)
High,
N (%)
v2
P-
value
Poor prognostic
group
199 (24) 36 (24) 163 (76)
Vascular invasion status
Negative 490 (67) 183 (30) 418 (70) 4.094
Positive 244 (33) 77 (24) 242 (77) 0.043
IHC/molecular subtypes
Luminal A 198 (25) 67 (34) 131 (66)
Luminal B 301 (37) 66 (22) 235 (78) 9.11
HER2 130 (16) 32 (25) 95 (75) 0.028
Triple-negative 178 (22) 44 (25) 134 (75)
Ki67
Negative (<10%) 230 (37) 71 (30) 159 (70) 4.030
Positive (≥10%) 395 (63) 93 (24) 302 (76) 0.045
The significant P-value in bold.
ALDH1A1, Aldehyde dehydrogenase family 1 member A1; IHC,
Immunohistochemistry; HER2, Human epidermal growth factor
receptor 2.
*Ndal status is based on the Nottingham system nodal stage (1 for
node-negative, 2 for 1–3 positive nodes and 3 for ≥4 positive
nodes).
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microwave (Whirlpool JT359 Jet Chef 1000W) for
20 min. The optimal dilution of ALDH1A1 antibody
in IHC was 1:100, and this was incubated for 1 h at
room temperature. Liver tissue was used as a positive
control, while the negative control was obtained by
omitting the primary antibody application step of the
staining protocol. In addition, prior to immunostain-
ing of the TMAs, full-face tissue sections from 20 ran-
domly selected BC FFPE were stained for ALDH1A1
and assessed for the distribution of staining to deter-
mine the appropriateness of using the TMAs.
A S S E S S M E N T O F A L D H 1 A 1 P R O T E I N E X P R E S S I O N
The TMA-stained slides were scanned at 920 magnifi-
cation into high-resolution digital images using a Nano-
Zoomer scanner (NanoZoomer; Hamamatsu Photonics,
Welwyn Garden City, UK). The images were viewed
using Xplore viewing software viewer (Philips, Guild-
ford, UK). ALDH1A1 staining was evaluated based on
semiquantitative scoring using the modified histochemi-
cal score (H-score), which estimated both the intensity
and the percentage of stained cells. The intensity was
assessed as 0 = negative, 1 = weak, 2 = moderate and
3 = strong, and the percentage (0–100%) of positive
stained tumour cells was evaluated. The final H-score
was calculated by multiplying the percentage of positive
cells (0–100) by the level of intensity (0–3), generating
a total range of 0–300.25 Furthermore, to test for the
interobserver scoring reproducibility, 10% of the cases
were randomly selected and double-scored. All cores
were scored independently, blinded to histopathological
data and patient outcomes.
T R A N S C R I P T O M I C A N A L Y S I S O F A L D H 1 A 1
The Molecular Taxonomy of Breast Cancer Interna-
tional Consortium (METABRIC) cohort of 1980 BC
patients was evaluated for ALDH1A1 mRNA expres-
sion and gene copy number (CN) aberration. In this
cohort, DNA/RNA were isolated from fresh frozen sam-
ples and transcription profiling was achieved using the
Illumina HT-12V3 platform. Details of the experimen-
tal and analytical methods used have been pub-
lished.26,27 In the cohort used for the current study,
patients with ER-positive and/or lymph node-negative
tumours did not receive adjuvant chemotherapy, while
those with ER-negative and/or lymph node-positive
tumours received this treatment. The relationships
between ALDH1A1 mRNA expression, CN aberration
and clinicopathological parameters were investigated.
The association between ALDH1A1 expression at both
protein and mRNA levels was investigated in
overlapping cases for both the METABRIC and Notting-
ham cohorts (n = 184 cases).
The clinicopathological parameters for this study
cohort are summarised in Table S2.
S T A T I S T I C A L A N A L Y S I S
IBM SPSS 24.0 (Chicago, IL, USA) software was used for
statistical analysis. Interobserver agreement was deter-
mined using kappa statistics. Furthermore, ALDH1A1
expression and other BCSCs were categorised at the pro-
teomic and transcriptomic levels using X-tile software
based on prediction of patient survival (X-tile Bioinfor-
matics Software, Yale University, version 3.6.1). Associ-
ations between the categorical groups of ALDH1A1
(including protein and mRNA levels and CN aberration)
and clinicopathological parameters and other BCSCs
were analysed using the v2 test. Associations with
patient outcome were assessed using Kaplan–Meier
curves and the log-rank test. Cox proportional hazard
regression models were built for multivariate survival
analyses to estimate the hazard ratios (HR) of ALDH1A1
adjusted by other well-known prognostic factors. A P-
value of less than 0.05 (two-tailed) was considered sig-
nificant in all statistical tests. This study followed the cri-
teria for the reporting recommendations for tumour
marker prognostic studies (REMARK).28
R E S E A R C H I N V O L V I N G H U M A N P A R T I C I P A N T S
A N D / O R A N I M A L S
This study was approved by the Nottingham Research
Ethics Committee 2 under the title ‘Development of a
molecular genetic classification of breast cancer’ and
the North West–Greater Manchester Central Research
Ethics Committee under the title ‘Nottingham Health
Science Biobank (NHSB)’, reference number 15/NW/
0685. All procedures performed in studies involving
human participants were in accordance with the ethi-
cal standards of the institutional and/or national
research committees and with the 1964 Helsinki decla-
ration and its later amendments or comparable ethical
standards. Release of data was also pseudoanonymised
as per the UK Human Tissue Act regulations. This arti-
cle does not contain any studies with animals per-
formed by any of the authors.
Results
A L D H 1 A 1 E X P R E S S I O N I N B C
We observed a high level of reproducibility of
ALDH1A1 scoring between the two observers as
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 77, 437–447.
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assessed by the kappa statistic of almost perfect agree-
ment (kappa = 0.865). ALDH1A1 immunostaining
showed homogeneous staining distribution through-
out the stained full-face tissue sections, which vali-
dated the use of TMAs, as shown in Figure S1B,C.
ALDH1A1 expression was localised in the cytoplasm
of the tumour cells with varying intensities, from
absent to strong (Figure 1A,B). However, ALDH1A1
was further expressed in immune infiltrates and the
stromal fibroblasts cells (Figure S1D,E). Moreover,
strong intensity of ALDH1A1 expression was
observed in the minority of tumour cells, while the
majority showed weak to moderate intensity.
Positive ALDH1A1 expression at the X-tile-gener-
ated cut-off point of H-score 5 (>5 H-score) was
observed in 663 of 930 (71%) cases. When
ALDH1A1 protein expression was examined in BC
molecular subtypes, ALDH1A1 was significantly
highly expressed in the highly proliferative tumours,
including luminal B (P = 0.028) (Table 1) although,
at the mRNA level, ALDH1A1 was also highly
expressed in 1405 of 1980 (71%) cases at cut-off
point (6.9 log fold-change) using X-tile. ALDH1A1
protein expression was not significantly associated
with ALDH1A1 mRNA expression (P > 0.05).
ALDH1A1 CN gain was observed in 35 of 1980
(1.7%) cases in the study cohort, and 32 of 1980
(1.6%) cases showed CN loss.
A L D H 1 A 1 A N D C L I N I C O P A T H O L O G I C A L
P A R A M E T E R S
ALDH1A1 protein expression was associated with
aggressive prognostic features of BC including high
grade (P = 0.007), high mitotic count (P = 0.004),
increased nuclear pleomorphism (P = 0.001), poor
NPI (P = 0.008), advanced nodal stage (four or
more positive nodes) (P = 0.002) and LVI
(P = 0.043), as shown in Table 1. High expression of
ALDH1A1 mRNA was positively associated with posi-
tive axillary nodes (P = 0.002), poor NPI
(P = 0.029), small tumour size (P < 0.0001) and
normal-like subtype (P < 0.0001), Table 2. There
was no significant association between ALDH1A1 CN
gain/loss and clinicopathological parameters
(P > 0.05).
A S S O C I A T I O N W I T H O T H E R B C S T E M C E L L
M A R K E R S
The correlation of ALDH1A1 mRNA and/or
ALDH1A1 protein expression with BCSC-like markers
was assessed using METABRIC (mRNA expression)
and the available markers in the cohort (IHC expres-
sion). The biomarkers selected for this analysis were
based on previous investigations reporting the marker
as being either a BCSC marker or associated with the
biological functions of ALDH1A1. ALDH1A1 was pos-
itively associated with CD24 (n = 578) (P = 0.018),
CD44 (n = 519) (P = 0.022), CD133 (n = 522)
(P = 0.039), TWIST (n = 631) (P < 0.0001), EPCAM
(n = 930) (P < 0.0001) and SOX9 (n = 929)
(P = 0.034), as shown in Table 3.
ALDH1A1 mRNA was positively associated with
CD44 (n = 1156) (P = 0.023), TWIST (n = 1159)
(P < 0.0001), SOX9 (n = 1529) (P = 0.037) and
EpCAM (n = 1343) (P = 0.012), as shown in
Table 4. There was no significant association between
ALDH1A1 CN gain/loss and any of the BCSC markers
investigated (P > 0.05).
O U T C O M E A N A L Y S I S
Univariate analysis showed that a high expression of
ALDH1A1 expression was associated with poor BCSS
(P < 0.0001). When the analysis was limited to the
Figure 1. Immunohistochemical (IHC) expression of aldehyde dehydrogenase family 1 member A1 (ALDH1) in invasive breast cancer (BC).
A, Negative expression of ALDH1A1. B, Positive IHC of ALDH1A1 expression. [Colour figure can be viewed at wileyonlinelibrary.com]
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 77, 437–447.
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molecular subtypes, high ALDH1A1 expression, at
the protein level, was associated with poor outcomes
in the TNBC (P = 0.003) and luminal B subtypes
(P = 0.042), but not in luminal A or HER2+ tumours
(P > 0.05) (Figure 2A–C). Cox proportional-hazards
models incorporating the standard prognostic param-
eters (tumour size, tumour grade and nodal stage)
showed that ALDH1A1 was an independent predictor
of poor prognosis [P = 0.001, HR = 1524, 95% confi-
dence interval (CI) = 1.180–1.968], as shown in
Table 5. However, ALDH1A1 lost its significant asso-
ciation with outcome when analysis was limited to
the luminal B and TNBC molecular subtypes, as
shown in Table S1.
Table 2. The association of ALDH1A1 expression and clini-
copathological parameters in invasive breast cancer
METABRIC cohort for mRNA expression
Parameters
ALDH1A1 expression (mRNA)
N (%)
Low, n
(%)
High, n
(%)
v2
P-value
Patient age (years)
<50 424 (21) 92 (25) 271(75) 2.12
≥50 1426 (79) 435 (29) 1055(71) 0.145
Tumour size (cm)
≤2 623 (32) 124 (21) 467 (79) 220.80
>2 1337 (68) 404 (32) 871 (68) <0.0001
Tumour grade
Grade 1 148 (19) 39 (24) 123 (76) 1.94
Grade 2 263 (34) 203 (28) 534 (72) 0.379
Grade 3 373 (47) 265 (29) 643 (71)
Axillary nodal stage*,*
Stage 1 1035 (52) 308 (31) 681 (69) 12.17
Stage 2 623 (31) 162 (28) 428 (73) 0.002
Stage 3 315 (16) 64 (21) 241 (79)
Nottingham Prognostic Index
Good prognostic
group
649 (34) 192 (30) 457 (70) 7.05
Moderate
prognostic
group
1049 (55) 305 (29) 744 (71) 0.029
Poor prognostic
group
193 (10) 39 (20) 154 (80)
PAM50 subtypes
Luminal A 689 (37) 184 (27) 505 (73) 51.35
Luminal B 459 (24) 154 (34) 305 (66) <0.0001
HER2** 308 (16) 107 (35) 201 (65)
Basal 233 (12) 72 (31) 161 (69)
Normal-like 196 (11) 17 (9) 179 (91)
The significant P-value in bold.
ALDH1A1, Aldehyde dehydrogenase family 1 member A1;
METABRIC, Molecular Taxonomy of Breast Cancer International
Consortium.
*Nodal status is based on the Nottingham system nodal stage (1
for node-negative, 2 for 1–3 positive nodes and 3 for ≥4 positive
nodes).
**Human epidermal growth factor receptor 2.
Table 3. Correlation of ALDH1A1 expression and other
breast cancer stem cell markers at protein expression level
Biomarkers
ALDH1A1 status (IHC)
N (%) Low, n (%) High, n (%)
v2
P-value
CD44 5.25
Negative 291 (56) 90 (31) 201 (69) 0.022
Positive 228 (44) 50 (22) 178 (78)
CD24 5.57
Negative 491 (85) 145 (29) 346 (71) 0.018
Positive 87 (15) 15 (17) 72 (83)
CD133 4.274
Negative 442 (85) 212 (34) 230 (66) 0.039
Positive 80 (15) 18 (22) 62 (78)
SOX9 4.48
Negative 377 (41) 121 (32) 256 (68) 0.034
Positive 552 (59) 142 (26) 410 (74)
EPCAM 18.40
Negative 640 (69) 209 (33) 431 (67) <0.0001
Positive 290 (31) 55 (19) 235 (81)
TWIST 17.38
Negative 266 (42) 96 (36) 170 (64) <0.0001
Positive 365 (58) 77 (21) 288 (79)
The significant P-value in bold.
ALDH1A1, Aldehyde dehydrogenase family 1 member A1; IHC,
Immunohistochemistry; HER2, Human epidermal growth factor
receptor 2.
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 77, 437–447.
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ALDH1A1 mRNA expression level showed that
high expression was associated with a favourable
patient outcome (P < 0.0001). However, no signifi-
cant association of ALDH1A1 mRNA expression was
identified with outcome in the BC molecular subtypes
(P > 0.05). Multivariant analysis showed that
ALDH1A1 mRNA expression was an independent pre-
dictor of good prognosis (P < 0.0001, HR = 0.640,
95% CI = 0.527–0.777), as shown in Table 5. There
was no significant association between ALDH1A1 CN
gain/loss and patient outcome (P > 0.05).
Discussion
ALDH1A1 plays a major role in the progression of
several solid tumours.6,29–31 Ginestier et al.4 have
reported that ALDH1A1 is a specific marker for iso-
lated BCSC. Furthermore, ALDH1A1 has been
reported as being a marker for CSC in solid cancers
such as lung13 and colorectal cancer.12. However,
Chang et al.12 showed that ALDH1A1 is associated
with improved patient outcome in ovarian cancer.
In this study, ALDH1A1 expression was assessed at
the genomic, transcriptomic and proteomic levels in
two large cohorts (METABRIC for both genomic, tran-
scriptomic and Nottingham series for proteomic
expression) of invasive BC, in order to understand its
prognostic significance and utility as a BCSC marker.
High protein and mRNA expression of ALDH1A1 was
noted in 71% of the BC tumours, which was much
higher than theoretically predicted. CSCs represent a
small percentage (0.05–1%) of tumour cell popula-
tions.32,33 Studies have reported that the expression
of ALDH1A1 is much lower (~50%) in other study
cohorts compared to the results of the current
study.34–36 However, the results of this study are in
agreement with those of another study.37 Such vari-
ability may have resulted from the use of different
cut-offs and the adopted definition of ALDH1A1 posi-
tivity. Investigating the prognostic significance of
ALDH1A1 in breast cancer using a large cohort, we
have derived a cut-off value based on the prediction
of patient survival, which might explain some of the
differences seen with other studies. Additionally, the
lack of concordance with other studies could partly
be explained by the difference in the scoring methods.
The H-scoring was used in this study, which is a
widely accepted system in both clinical and research
settings, and previous studies have used other scoring
systems.
In addition, it could be speculated that the diffuse
immunostaining of ALDH1A1 expression as an indi-
vidual tissue marker may not predict the BCSCs popu-
lation; rather, a combination of expression of more
than one BCSC marker may more precisely determine
CSCs using IHC. For example, Neumeister et al.38
showed that both ALDH1A1 and CD44 expression in
combination, using multiplex immunofluorescent in
BC tissues, can predict patient survival rather than
the isolated assessment of either. Furthermore, in the
current study we observed strong immunoreactivity
of ALDH1A1 in a minority of malignant cell popula-
tions, which could indicate that only this subpopula-
tion may represent BCSCs. A previous study has also
demonstrated low levels of strong ALDH1 expression
in BC with only focal positivity, which may be consis-
tent with the concept of CSCs that are represented by
only a subpopulation of tumour cells.39
Table 4. Correlation of ALDH1A1 expression and other
breast cancer stem cell markers at mRNA expression level
Biomarkers
ALDH1A1 status (mRNA)
N (%) Low, n (%) High, n (%)
v2
P-value
CD44
Negative 907 (78) 260 (29) 647 (71) 5.17
Positive 249 (22) 90 (36) 159 (64) 0.023
CD24
Negative 697 (41) 199 (29) 498 (71) 0.49
Positive 1009 (59) 304 (30) 705 (70) 0.482
CD133
Negative 1027 (63) 313 (31) 711 (69) 1.87
Positive 596 (37) 163 (27) 433 (73) 0.170
SOX9
Negative 732 (48) 420 (57) 312 (43) 4.35
Positive 797 (52) 499 (63) 298 (37) 0.037
EPCAM
Negative 917 (68) 521 (57) 396 (43) 6.359
Positive 426 (32) 273 (64) 153 (36) 0.012
TWIST
Negative 948 (82) 398 (42) 550 (58) 47.56
Positive 211 (18) 35 (17) 176 (83) <0.0001
The significant P-value in bold.
ALDH1A1, Aldehyde dehydrogenase family 1 member A1.
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Identification of CSCs is commonly accomplished
using several biomarkers. There is no universal mar-
ker, nor is there a consensus for CSCs markers for all
cancer types, and some molecules are frequently
shared across entities. Al-Hajj et al.40 identified a
BCSC with respect to cell surface markers (CD44/
CD24) shown to drive tumour growth. Furthermore,
Ahmed et al.22 showed that expression of CD44 and
CD24 in BC tissue samples was significantly associ-
ated with more aggressive behaviour and worse
patient outcomes. The findings of the current study
indicate a significant correlation between the
ALDH1A1 and CD44+/CD24+ phenotypes. Further-
more, ALDH1A1 also showed a significant positive
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Figure 2. Kaplan–Meier survival plots for immunohistochemical expression of aldehyde dehydrogenase family 1 member A1 (ALDH1). A–C,
BCSS in the whole breast cancer (BC) cohort, in triple-negative (TN) BC cases and in luminal B subtype, respectively. [Colour figure can be
viewed at wileyonlinelibrary.com]
Table 5. Multivariate Cox regression hazard analysis including BC standard prognostic clinicopathological parameters and
ALDH1A1 IHC and mRNA expression in whole cohort
Parameters
IHC expression mRNA expression
P-value Hazard ratio 95% CI P-value Hazard ratio 95% CI
ALDH1A1 0.001 1.524 1.180–1.968 <0.0001 0.640 0.527–0.777
Tumour size 0.008 1.395 1.089–1.785 <0.0001 1.516 1.203–1.910
Tumour grade <0.0001 1.846 1.529–2.273 <0.0001 1.364 1.163–1.599
Axillary nodal stage <0.0001 1.790 1.531–2.132 <0.0001 1.92 1.703–2.174
The significant P-value in bold.
ALDH1A1, Aldehyde dehydrogenase family 1 member A1; BC, Breast cancer; IHC, Immunohistochemistry; CI, Confidence interval.
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association with other BCSC markers, including
CD133, TWIST1, SOX9 and EPCAM, at protein
expression level. CD133/prominin 1 is a promising
BCSC candidate marker, and maintains the character-
istics of self-renewal, high proliferation and drug
resistance.21 Recently, an assessment of CD133
expression in BC concluded that its overexpression is
likely a stem cell feature and prognostic marker in
BC.41 EPCAM and TWIST1 are well-established BCSCs
and epithelial–mesenchymal transition (EMT) markers
that can maintain self-renewal, the pluripotent phe-
notype and EMT in cancer progression.42,43 Domenic
et al.44 reported that SOX9 expression may maintain
human breast luminal progenitor cells, and may be
associated with more aggressive tumours in BC.45
The results of this study indicate that ALDH1A1 may
be used not only as a CSC marker, but also as a prog-
nostic and predictive marker, in BC. The protein
expression of ALDH1A1 was more frequent in the
highly proliferative (luminal B and TNBC) tumours,
which suggests that ALDH1A1 may contribute to cell
proliferation and tumorigenesis of BC.46 Furthermore,
in agreement with another study,47 the current study
showed that ALDH1A1 is positively associated with
the proliferation marker Ki67. ALDH1A1 mainly
catalyses retinaldehyde to retinoic acid, which subse-
quently binds and activates the retinoic acid or the
retinoid X receptors in the nucleus of the cell, and
thus promotes target gene expression. The down-
stream genes of the retinoic acid pathway are also
involved in the differentiation and proliferation of
tumour cells.45 The study results demonstrate that
high expression of ALDH1A1 at both protein and
mRNA levels has a positive association with poor
prognostic features. Fei et al.39 concluded that
ALDH1A1 predicts patient outcome in TNBC.
Another study48 reported that high expression of
ALDH1A1 is associated with larger tumour size,
higher grade and advanced tumour stage in BC,
which is in agreement with the current study. The
results of the current study showed high expression
of ALDH1A1 in the luminal B and TN subtypes,
which could further reflect the heterogeneity of BC
with respect to stemness marker expression. Impor-
tantly, ALDH1A1 was an independent prognostic
marker in BC, which may have clinical relevance in
terms of the potential to improve survival rate predic-
tion, especially in these specific subtypes.48
Contradictory findings between protein levels and
mRNA levels were observed in the outcome analysis
for this study, but they were similar to other study
findings.49 ALDH1A1 mRNA expression showed an
association with improved BC patients’ survival.
Another study49 indicated that ALDH1A1 expression
was associated with good outcomes in TNBC.
Sj€ostr€om et al.50 reported that stromal ALDH1A1 was
associated with better distant disease-free survival in
BC. A possible explanation of the survival discrepancy
in mRNA expression is that the stromal expression of
ALDH1A1 was not completely removed during tissue
processing in the process of RNA extraction. This
observation suggests that ALDH1A1 expression in
stromal cells might be in cytotoxic T, B or dendritic
cells, which are known to suppress tumour progres-
sion.49 For IHC expression in this study, we only con-
sidered ALDH1A1 protein expression in the invasive
tumour cells. Moreover, there was no significant cor-
relation between ALDH1A1 protein and mRNA
expression in a subset of 184 cases, which could be
attributed to the same reason.
Conclusions
This study has demonstrated and confirmed that
ALDH1A1 expression is associated with poor prog-
nostic characteristics and survival outcomes in BC.
Expression in BC was also associated with stem cell
markers. The combination of the expression of
ALDH1A1 with other BCSC markers in BC tissue
samples may, therefore, serve as a tool to accurately
identify the BCSC subpopulation.
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Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Figure S1. (A) Western blot of rabbit monoclonal
anti-ALDH1A1 antibody shows a single specific band
(left green band) at the expected molecular weight
(56 kDa) in HeLa cell lysates. The red bands repre-
sent the beta-actin (positive control) at 42 kDa
molecular weight. (B, C) Homogenous expression of
ALDH1A1 in invasive breast cancer. (D, E) ALDH1A1
expression in stromal cells.
Table S1. Multivariate Cox regression hazard model
including other prognostic clinicopathological param-
eters and ALDH1A1 (IHC) in luminal B and TNBC.
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